Skip to Content

Desoxyn Side Effects

Generic Name: methamphetamine

Note: This page contains information about the side effects of methamphetamine. Some of the dosage forms included on this document may not apply to the brand name Desoxyn.

Not all side effects for Desoxyn may be reported. You should always consult a doctor or healthcare professional for medical advice. Side effects can be reported to the FDA here.

For the Consumer

Applies to methamphetamine: oral tablet, oral tablet extended release

In addition to its needed effects, some unwanted effects may be caused by methamphetamine (the active ingredient contained in Desoxyn). In the event that any of these side effects do occur, they may require medical attention.

You should check with your doctor immediately if any of these side effects occur when taking methamphetamine:

  • Agitation
  • delusions
  • hallucinations
Incidence not known
  • Blurred vision
  • chest discomfort or pain
  • dark-colored urine
  • difficulty breathing
  • dizziness
  • faintness
  • false or unusual sense of wellbeing
  • fast, pounding, or irregular heartbeat or pulse
  • fever
  • headache
  • muscle cramps or spasms
  • muscle pain or stiffness
  • pounding in the ears
  • restlessness
  • shakiness in the legs, arms, hands, or feet
  • swelling of the feet or lower legs
  • trembling or shaking of the hands or feet
  • trouble sleeping
  • twitching, twisting, or uncontrolled repetitive movements of the tongue, lips, face, arms, or legs
  • uncontrolled vocal outbursts and tics
  • unusual tiredness or weakness

Some of the side effects that can occur with methamphetamine may not need medical attention. As your body adjusts to the medicine during treatment these side effects may go away. Your health care professional may also be able to tell you about ways to reduce or prevent some of these side effects. If any of the following side effects continue, are bothersome or if you have any questions about them, check with your health care professional:

Incidence not known
  • Bad, unusual, or unpleasant (after) taste
  • change in taste
  • constipation
  • decreased interest in sexual intercourse
  • dry mouth
  • hives or welts
  • inability to have or keep an erection
  • indigestion
  • itching
  • loss in sexual ability, desire, drive, or performance
  • passing of gas
  • redness of the skin
  • skin rash
  • weight loss

For Healthcare Professionals

Applies to methamphetamine: oral tablet, oral tablet extended release


Cardiovascular effects have included palpitations, tachycardia, and elevated blood pressure. Sudden death, cardiomyopathy, stroke, and myocardial infarction have been reported rarely.[Ref]

The results of case-controlled study indicate that methamphetamine use among young patients (less than 45-years-old) not only increases the risk of developing cardiomyopathy but also of developing a more severe form of cardiomyopathy. However, it has been suggested that myocardial pathology may be reversible with early cessation of use.[Ref]

Nervous system

Nervous system effects have included overstimulation, restlessness, dizziness, insomnia, euphoria, dyskinesia, dysphoria, tremor, headache, exacerbation of motor and phonic tics and Tourette's syndrome. Long-term neurotoxicity has been associated with methamphetamine (the active ingredient contained in Desoxyn) abuse.[Ref]


According to one review, xerostomia secondary to chronic methamphetamine (the active ingredient contained in Desoxyn) use can result in significant oral health issues such as dental caries and accelerated tooth wear from bruxism.[Ref]

Gastrointestinal effects have included dry mouth, unpleasant taste, diarrhea, constipation, (undesired) anorexia and weight loss, and other disturbances. One study has reported that recent methamphetamine use was significantly predictive of giant ulcer formation.[Ref]


Dermatologic effects have included urticaria.[Ref]


Endocrine side effects have included impotence and changes in libido.[Ref]


Children aged 7 to 10 years randomized to received methylphenidate (vs. placebo) were found to experience a temporary slowing in growth rate without evidence of growth rebound during this period. It is unknown whether chronic use of amphetamines cause a similar suppression of growth, but it is anticipated that they will.[Ref]

Other effects have included a significant elevation (highest in the evening) of the plasma corticosteroid levels and temporary growth suppression associated with long-term use. Amphetamines may interfere with urinary steroid determination.[Ref]


Psychiatric side effects including psychotic episodes at recommended doses have been reported rarely.[Ref]

Persistent psychiatric symptoms in methamphetamine users (including psychotic symptoms) may be attributable to the reduction of dopamine transporter activity.[Ref]


Ocular side effects including visual disturbances such as difficulties with accomodation and blurred vision have been associated with stimulant therapy.


1. "Product Information. Desoxyn (methamphetamine)" Abbott Pharmaceutical, Abbott Park, IL.

2. Ragland AS, Ismail Y, Arsura EL "Myocardial infarction after amphetamine use." Am Heart J 125 (1993): 247-9

3. Yeo KK, Wijetunga M, Ito H, et al. "The association of methamphetamine use and cardiomyopathy in young patients." Am J Med 120 (2007): 165-71

4. Ayres PR "Amphetamine cardiomyopathy [letter]." Ann Intern Med 98 (1983): 110

5. Bashour TT "Acute myocardial infarction resulting from amphetamine abuse: a spasm- thrombus interplay." Am Heart J 128 (1994): 1237-9

6. Smith HJ, Roche AH, Jausch MF, Herdson PB "Cardiomyopathy associated with amphetamine administration." Am Heart J 91 (1976): 792-7

7. Ernst T, Chang L, Leonido-Yee M, Speck O "Evidence for long-term neurotoxicity associated with methamphetamine abuse: a 1H MRS study." Neurology 54 (2000): 1344-9

8. Larkin M "Methamphetamine use could lead to long-term brain damage." Lancet 355 (2000): 1162

9. Pecha RE, Prindiville T, Pecha BS, Camp R, Carroll M, Trudeau W "Association of cocaine and methamphetamine use with giant gastroduodenal ulcers." Am J Gastroenterol 91 (1996): 2523-7

10. Donaldson M, Goodchild JH "Oral health of the methamphetamine abuser." Am J Health Syst Pharm 63 (2006): 2078-2082

11. Sekine Y, Iyo M, Ouchi Y, Matsunaga T, Tsukada H, Okada H, Yoshikawa E, Futatsubashi M, Takei N, Mori N "Methamphetamine-related psychiatric symptoms and reduced brain dopamine transporters studied with PET." Am J Psychiat 158 (2001): 1206-14

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate safety, effectiveness, or appropriateness for any given patient. does not assume any responsibility for any aspect of healthcare administered with the aid of materials provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the substances you are taking, check with your doctor, nurse, or pharmacist.